Induction of TRM cells can enhance the efficacy of cancer vaccines (11) and increase the response rate when using anti-PD-1 antibodies to reverse tumor-induced T cell exhaustion in NSCLC patients (12, 13). The gene discussed is PDCD1; the disease is neoplasm.